[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jiuda Zhao\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":144},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,76,102,127],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100562319","study-on-the-impact-of-electroacupuncture-combined-with-self-acupressure-on-the-quality-of-life-of-patients-with-early-stage-breast-cancer-undergoing-chemotherapy-100562319",false,"NCT06601621","Study on the Impact of Electroacupuncture Combined With Self-Acupressure on the Quality of Life of Patients With Early-Stage Breast Cancer Undergoing Chemotherapy","Inclusion Criteria:\n\n1. Aged 18 years or older and aged 75 years or younger, inclusive. with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;\n2. Patients who have not received prior chemotherapy and are scheduled to receive at least 4 cycles of adjuvant or neoadjuvant chemotherapy or combination targeted therapy;\n3. Normal organ function with platelets ≥ 100\\*10\\^9\u002F L, hemoglobin ≥ 90 g\u002FL, serum creatinine ≤ 1.5 mg\u002Fdl (133 mmol\u002FL), or creatinine clearance ≥ 60 ml\u002Fmin, total bilirubin ≤ 1.5 times the upper limit of normal (ULN), alanine aminotransferase ≤ 2.5 times ULN, and aspartate aminotransferase ≤ 2.5 times ULN;\n4. Premenopausal women need appropriate contraception;\n5. Ability to understand the study well and complete the study questionnaire.\n\nExclusion Criteria:\n\n1. Patients with needle phobia or allergy to stainless steel needles; and\n2. Current diagnosis of mental illness (e.g., major depression, obsessive-compulsive disorder, or schizophrenia);\n3. History of autoimmune diseases, blood disorders, or organ transplantation, or long-term use of hormones or immunosuppressants;\n4. Comorbid bleeding disorders or thyroid dysfunction;\n5. Implantation of a pacemaker; pregnancy or breastfeeding;\n6. A plan for adjuvant radiotherapy in the upcoming chemotherapy cycle;\n7. Current active infection;\n8. Acupuncture treatment within the last four weeks;\n9. Patients who are allergic to the drugs used;\n10. Use of other Traditional Chinese Medicine (TCM) techniques such as Chinese herbs in the next chemotherapy cycle.","ALL","18 Years","75 Years",{"count":19,"type":20},192,"ESTIMATED","INTERVENTIONAL",[23],"NA","This randomized controlled clinical trial aims to evaluate the effect of electroacupuncture combined with self-acupressure on the quality of life of early-stage breast cancer patients receiving chemotherapy.",[26,27,28,29,30],"Electroacupuncture","Quality of Life (QOL)","Acupressure","Breast Cancer","Chemotherapy",[32,33,34,35],"electroacupuncture","self-acupressure","Quality of life (QOL)","breast cancer","RECRUITING","2026-02-11",{"date":39,"type":40},"2026-02-12","ACTUAL",{"date":42,"type":40},"2024-10-19",{"date":44,"type":20},"2026-04-30",{"name":46,"class":47},"Jiuda Zhao","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":48},"100589323","phase-3-electroacupuncture-for-chemotherapy-induced-gi-symptom-clusters-in-breast-cancer-100589323","NCT06952920","Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer","Electroacupuncture for Managing Chemotherapy-Induced Gastrointestinal Symptom Clusters in Patients With Breast Cancer","Inclusion Criteria:\n\n1. Pathologically confirmed stage I-III breast cancer;\n2. An Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1;\n3. Age between 18 and 75 years;\n4. Scheduled to receive highly emetogenic chemotherapy regimens, such as EC (epirubicin + cyclophosphamide) or platinum-based regimens, during the first cycle of neoadjuvant\u002Fadjuvant chemotherapy;\n5. No prior acupuncture treatment within one month before enrollment;\n6. Voluntary participation in the study with written informed consent obtained; (7) An expected survival of at least 3 months;\n\n(8) Premenopausal women must agree to use contraception during the study period; (9) Adequate bone marrow, liver, and kidney function as defined by standard laboratory criteria.\n\nExclusion Criteria:\n\n1. Patients with advanced-stage cancer;\n2. Those undergoing concurrent chemoradiotherapy;\n3. Individuals with severe impairment of vital organ function who cannot tolerate standard-dose chemotherapy;\n4. Patients with contraindications to acupuncture, such as active skin infections;\n5. Those with digestive system diseases accompanied by nausea and vomiting symptoms that may interfere with accurate assessment;\n6. Patients with a history of xerostomia;\n7. Individuals with known allergies to the study drugs;\n8. Pregnant or breastfeeding patients;\n9. Individuals currently using medications with antiemetic activity, such as 5-HT3 receptor antagonists, corticosteroids (except at physiological doses), dopamine receptor antagonists, minor tranquilizers, antihistamines, and benzodiazepines (except for nighttime sedation);\n10. Patients with seizure disorders requiring anticonvulsant therapy;\n11. Those receiving thiazides as chronic antipsychotic medications;\n12. Those with known arrhythmias, uncontrolled congestive heart failure, or acute myocardial infarction.",{"count":57,"type":20},388,[59],"PHASE3","This study aims to elucidate the therapeutic efficacy of electroacupuncture in managing chemotherapy-induced gastrointestinal symptom clusters through clinical research. Building upon this foundation, multi-omics analyses will be conducted to investigate the regulatory effects and underlying mechanisms of electroacupuncture on gastrointestinal symptoms. Ultimately, genomic studies will be performed to further clarify the key targets of electroacupuncture intervention, thereby providing high-level evidence-based medical support and theoretical foundations for optimizing electroacupuncture strategies in addressing chemotherapy-induced gastrointestinal symptoms in patients with cancer.",[62,26,63],"Standard Quadruple Antiemetic Therapy","Chemotherapy-induced Gastrointestinal Symptom Cluster",[35,65,66,32,67],"chemotherapy","standard quadruple antiemetic therapy","chemotherapy-induced gastrointestinal symptom cluster","2025-12-08",{"date":70,"type":40},"2025-12-15",{"date":72,"type":40},"2025-08-21",{"date":74,"type":20},"2028-06-30",{"name":46,"class":47},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":48},"100531466","phase-3-electroacupuncture-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-patients-with-breast-cancer-100531466","NCT06200168","Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer","A Study on Electroacupuncture Combined With Olanzapine-contained Four-drug Antiemetic Therapy for the Prevention of Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer (ECO Study)","Inclusion Criteria:\n\n1. Aged 18 years or older and aged 75 years or younger, of any nationality;\n2. Eastern Cooperative Oncology Group performance status of 0-2;\n3. Patients with breast cancer, with no restrictions on molecular typing; early-stage patients must not have undergone prior chemotherapy, while advanced-stage patients must be candidates for first-line chemotherapy and have declined neoadjuvant or adjuvant chemotherapy for over 3 months. All patients must receive highly emetogenic chemotherapy (HEC) based on anthracycline chemotherapy with cyclophosphamide (EC or AC) or carboplatin (AUC≥4)\u002Fcisplatin;\n4. Predicted life expectancy of ≥3 months;\n5. Adequate bone marrow, kidney, and liver function;\n6. Adequate contraception if premenopausal women;\n7. Written informed consent by the patient before enrolment.\n\nExclusion Criteria:\n\n1. Patients already submitted to chemotherapy;\n2. Is scheduled to receive any non-HEC on Day 1;\n3. Is scheduled to receive any chemotherapy on days 2-4 after HEC;\n4. Received or is scheduled to receive radiation therapy to the abdomen, pelvis, head and neck within 1 week prior to Day 1 or between Days 1 to 5 in cycle 1;\n5. Has symptomatic primary or metastatic symptomatic central nervous system malignancy causing nausea and\u002For vomiting;\n6. Have ongoing emesis or CTCAE grade 2 or greater nausea;\n7. Significant medical or mental conditions;\n8. Any allergies to study drug, antiemetics or dexamethasone;\n9. Significantly abnormal laboratory values (platelets, coagulation indexes, absolute neutrophils, AST, ALT, bilirubin or creatinine);\n10. Patients who are pregnant or breast-feeding;\n11. Inflammatory skin reaction;\n12. Has lymphedema in acupuncture stimulation area;\n13. Patients who are afraid of electroacupuncture stimulation or allergic to stainless steel needles;\n14. Received acupuncture treatments for any conditions less than 4 weeks before HEC;\n15. Currently using drugs with antiemetic activity (e.g., 5-HT3 receptor antagonists, corticosteroids (except when used at physiological doses), dopamine receptor antagonists, minor tranquilizers, antihistamines, and benzodiazepines (except for nocturnal sedation));\n16. Patients with concomitant severe diseases or with a predisposition to emesis such as gastrointestinal obstruction, active peptic ulcer, and hypercalcemia and symptomatic brain metastasis;\n17. Has a convulsive disorder requiring anticonvulsant treatment;\n18. Patients administered thioridazine as a chronic antipsychotic medication (patients are allowed to receive prochlorperazine and other phenothiazines as a rescue antiemetic treatment);\n19. Concurrent treatment with quinolone antibiotics;\n20. Has a history of chronic alcoholism (determined by the investigator);\n21. Known arrhythmias, uncontrolled congestive heart failure, or acute myocardial infarction within the past six months;\n22. Has a history of uncontrolled diabetes (e.g., using insulin or oral hypoglycemic agents).",true,{"count":85,"type":20},370,[59],"This randomized controlled phase III trial aims to evaluate the use of electroacupuncture in combination with olanzapine-containing standard quadruple antiemetic drugs for the treatment of nausea and vomiting induced by highly emetogenic chemotherapy (HEC) in patients with breast cancer. Furthermore, it will analyze the relationship between single nucleotide polymorphism and electroacupuncture treatment for chemotherapy-induced nausea and vomiting.",[26,89,90],"Olanzapine-contained Four-drug Antiemetic","Nausea and Vomiting",[32,92,93,35,65],"olanzapine-contained four-drug antiemetic","nausea and Vomiting","2025-03-27",{"date":96,"type":40},"2025-04-02",{"date":98,"type":40},"2024-01-16",{"date":100,"type":20},"2026-12-31",{"name":46,"class":47},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":21,"phases":111,"briefSummary":112,"conditions":113,"keywords":118,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":125,"locationsCount":126},"100565457","effect-of-vitamin-d-supplementation-on-the-efficacy-and-adverse-effects-of-neoadjuvant-therapy-in-patients-with-breast-cancer-100565457","NCT06642428","Effect of Vitamin D Supplementation on the Efficacy and Adverse Effects of Neoadjuvant Therapy in Patients with Breast Cancer","Inclusion Criteria:\n\n1. Age between 18 and 80 years, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n2. Primary diagnosis of breast cancer confirmed by preoperative pathological examination.\n3. Serum 25(OH)D levels less than 20 ng\u002Fml (50 nmol\u002FL).\n4. Patients who have not previously received chemotherapy and who plan to undergo at least 4 cycles of 5.neoadjuvant chemotherapy or combined targeted therapy.\n\n6.Life expectancy of at least 6 months. 7.No other uncontrolled benign diseases at the time of recruitment. 8.All patients must have complete clinical medical records. 9.Willingness to voluntarily sign an informed consent form.\n\nExclusion Criteria:\n\n1. History of invasive breast cancer.\n2. Prior systemic treatment for the treatment or prevention of breast cancer.\n3. Known allergic reactions to vitamin D or calcium compounds.\n4. Comorbidities that may affect vitamin D or calcium balance or bone health.\n5. Vitamin D or calcium supplementation in the past 3 months.\n6. Presence of other tumors.\n7. Pregnant or lactating women.\n8. Individuals who do not wish to participate in the study.","80 Years",{"count":110,"type":20},140,[23],"This randomized controlled Phase III trial was designed to evaluate the impact of supplemental vitamin D (VD) on the efficacy and side effects of neoadjuvant therapy in patients with breast cancer.",[114,115,29,116,117,30],"Vitamin D","Neoadjuvant Therapy","Adverse Reaction","Efficacy",[114,29,116,117],"2025-01-16",{"date":121,"type":40},"2025-01-17",{"date":123,"type":40},"2024-10-18",{"date":44,"type":20},{"name":46,"class":47},2,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":108,"enrollmentInfo":133,"targetDuration":4,"studyType":21,"phases":135,"briefSummary":136,"conditions":137,"keywords":138,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":143,"locationsCount":126},"100565458","effect-of-vitamin-d-supplementation-on-chemotherapy-side-effects-after-adjuvant-chemotherapy-for-breast-cancer-100565458","NCT06642441","Effect of Vitamin D Supplementation on Chemotherapy Side Effects After Adjuvant Chemotherapy for Breast Cancer","Inclusion Criteria:\n\n1. Age between 18 and 80 years, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n2. Primary diagnosis of breast cancer confirmed by preoperative pathological examination.\n3. Serum 25(OH)D levels less than 20 ng\u002Fml (50 nmol\u002FL).\n4. Patients who have not previously received chemotherapy and who plan to undergo at least 4 cycles of\n5. Patients with adjuvant chemotherapy or combined targeted therapy.\n6. Life expectancy of at least 6 months.\n7. No other uncontrolled benign diseases at the time of recruitment.\n8. All patients must have complete clinical medical records.\n9. Willingness to voluntarily sign an informed consent form.\n\nExclusion Criteria:\n\n1. History of invasive breast cancer.\n2. Prior systemic treatment for the treatment or prevention of breast cancer.\n3. Known allergic reactions to vitamin D or calcium compounds.\n4. Comorbidities that may affect vitamin D or calcium balance or bone health.\n5. Vitamin D or calcium supplementation in the past 3 months.\n6. Presence of other tumors.\n7. Pregnant or lactating women.\n8. Individuals who do not wish to participate in the study.",{"count":134,"type":20},100,[23],"This randomized controlled Phase III trial was designed to evaluate the effect of vitamin D supplementation (VD) on chemotherapy side effects following adjuvant chemotherapy in breast cancer",[114,30,29,116],[114,29,116],{"date":121,"type":40},{"date":141,"type":40},"2024-12-01",{"date":44,"type":20},{"name":46,"class":47},""]